Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): a randomised controlled trial with cost-effectiveness analysis

Roland L Featherstone,1 Joanna Dobson,2 Jörg Ederle,1 David Doig,1 Leo H Bonati,1,3 Stephen Morris,4 Nishma V Patel4 and Martin M Brown1*

1Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, University College London, London, UK
2Department of Medical Statistics Unit, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
3Department of Neurology and Stroke Centre, University Hospital Basel, Basel University, Basel, Switzerland
4Department of Applied Health Research, University College London, London, UK

*Corresponding author

Declared competing interests of authors: none

Published March 2016
DOI: 10.3310/hta20200

Scientific summary

The International Carotid Stenting Study

Health Technology Assessment 2016; Vol. 20: No. 20
DOI: 10.3310/hta20200

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Atherosclerotic stenosis of the carotid artery is a major cause of stroke. Carotid endarterectomy (CEA) has been shown in previous trials to significantly reduce the risk of stroke in patients with symptomatic atherosclerotic carotid stenosis. However, carotid artery stenting (CAS) is considered to be less invasive than CEA and has advantages in terms of patient comfort because the procedure avoids an incision in the neck and is conducted under local anaesthesia. At the time of the inception of the International Carotid Stenting Study (ICSS), stenting was being widely adopted for the treatment of carotid stenosis on the basis of case series in the absence of randomised trial evidence. ICSS was initiated to provide such evidence.

Objectives

The primary objective of ICSS was to compare the long-term rate of fatal or disabling stroke in patients randomly allocated a treatment policy of referral for carotid stenting compared with referral for carotid surgery.

Secondary analyses examined:

- short-term and long-term differences in mortality and morbidity related to treatment
- the short-term risk of cerebral ischaemia assessed by magnetic resonance imaging (MRI) after treatment
- predictors of the perioperative risks of treatment
- the rate of restenosis during follow-up
- differences in functional outcome during follow-up
- the cost-effectiveness of carotid stenting compared with surgery.

Methods

The ICSS was an international, multicentre, randomised controlled, open, prospective clinical trial comparing carotid surgery with carotid stenting.

Participants

Patients of either sex over the age of 40 years with symptomatic atherosclerotic stenosis of the carotid artery.

Inclusion criteria

- Symptomatic, extracranial, internal or bifurcation atheromatous carotid artery stenosis suitable for both stenting and surgery, and deemed to require treatment.
- The severity of the stenosis of the randomised artery had to be at least 50% (as measured by the North American Symptomatic Carotid Endarterectomy Trial method or non-invasive equivalent).
- Symptoms must have occurred in the 12 months before randomisation. It was recommended that the time between symptoms and randomisation should be < 6 months, but patients with symptoms between 6 months and 12 months could be included if treatment was indicated.
- The patient had to be clinically stable following their most recent symptoms.
- Patients could only be randomised if the investigator was uncertain which of the two treatments was best for that patient at that time.
Exclusion criteria

- Patients unable or unwilling to give informed consent or participate in follow-up.
- Patients who had previously had a major stroke with no useful recovery of function.
- Patients with a stenosis unsuitable for stenting prior to randomisation because of one or more of:
  - tortuous anatomy proximal or distal to the stenosis
  - presence of visible thrombus
  - proximal common carotid artery stenotic disease
  - pseudo-occlusion (‘string sign’).
- Patients not suitable for surgery owing to anatomical factors (e.g. high stenosis).
- Patients in whom it was planned to carry out coronary artery bypass grafting or other major surgery within 1 month of carotid stenting or endarterectomy.
- Carotid stenosis caused by non-atherosclerotic disease (e.g. dissection, fibromuscular disease or neck radiotherapy).
- Previous CEA or stenting in the randomised artery.
- Patients in whom common carotid artery surgery was planned.
- Patients medically not fit for surgery.
- Patients who had a life expectancy of <2 years owing to a pre-existing condition (e.g. cancer).

Randomisation

Patients were randomly allocated in equal proportions to endarterectomy or stenting. Randomisation was performed by a telephone call or fax to a computerised service provided by the Oxford Clinical Trials Service Unit and was stratified by centre with minimisation of the main risk factors balanced between the arms.

Interventions

Endarterectomy was carried out as soon as possible after randomisation by a consultant surgeon approved by the accreditation committee, using procedures standard at the centre.

Stenting was carried out as soon as possible after randomisation by an approved consultant interventionist using an approved stent. A cerebral protection system was used whenever the operator thought that one could be safely deployed.

Data collected at baseline

Baseline data collected at randomisation included demographic data, medical risk factors, symptoms and an assessment of disability using the modified Rankin Scale (mRS), antiplatelet therapy and blood pressure, films and reports of pre-randomisation brain imaging, and the results of duplex ultrasound (DUS).

Follow-up

Patients were followed up by a neurologist or a stroke physician at 30 days after treatment, 6 months after randomisation and, then, annually. At each visit, levels of stroke-related disability were assessed using the mRS and any outcome events were notified to the Central Trial Office. A DUS of the carotid arteries was performed at each follow-up visit. In addition to the clinical data, patients were asked to complete a European Quality of Life-5 Dimensions-3 level response (EQ-5D-3L™) questionnaire to assess health-related quality of life at baseline and each follow-up. Utility values calculated from the EQ-5D-3L questionnaire responses were used to calculate quality-adjusted life-years (QALYs) for every patient. Patients were followed up to the end of 2011 (a maximum of 10 years after randomisation).
**Resource use and costs**
For every patient, the cost of the index procedure and the cost of follow-up were calculated using resource-use data collected prospectively. The former included: surgeon and radiologist time; operating theatre time, including nursing staff, drugs, consumables and overheads; anaesthesia; materials and devices, including stents, shunts, patches, cerebral protection devices, catheters, wires and sheaths; and length of hospital stay in the intensive care unit (ICU) and inpatient ward. The latter included additional carotid artery procedures; complications within 30 days of index procedure [fatal and non-fatal myocardial infarction (MI), severe haematoma and disabling cranial nerve palsy]; imaging tests; drug treatment; and non-disabling, disabling and fatal strokes. Length of stay in the ICU was not collected for individual patients, but mean values were collected by centre. From these data we assumed that where patients were admitted to the ICU post-operatively, it was for 1 day.

**Results**
Between May 2001 and October 2008, 1713 patients from 50 centres in the UK, mainland Europe, Australia, New Zealand and Canada were randomised. Patients were followed up for a median of 4.2 years and a maximum of 10 years after randomisation, amounting to 7355 patient years of follow-up.

**Short-term outcomes**
In the intention-to-treat (ITT) analysis, the risk of stroke, death or procedural MI between randomisation and 120 days was significantly higher in patients in the stenting group than in patients in the endarterectomy group (8.5% vs. 5.1%), representing an estimated 120-day absolute risk difference of 3.3% [95% confidence interval (CI) 0.9% to 5.7%] with a hazard ratio (HR) in favour of surgery of 1.69 (95% CI 1.16 to 2.45, log-rank \( p = 0.006 \)). There was no significant difference in the rate of disabling stroke or death between groups (4.0% in the stenting group vs. 3.2% in the endarterectomy group). The observed treatment effect was largely driven by the higher number of non-disabling strokes in the stenting group. Cranial nerve palsies were almost completely avoided by stenting [risk ratio (RR) 0.02, 95% CI 0.00 to 0.16; \( p < 0.0001 \)]. There were also fewer haematomas in the stenting group than in the endarterectomy group (RR 0.59, 95% CI 0.38 to 0.93; \( p = 0.0197 \)). Stenting was associated with a higher risk of stroke within 30 days of treatment compared with endarterectomy in patients with an age-related white-matter changes (ARWMC) score on baseline brain imaging of 7 or more (HR for any stroke 2.98, 95% CI 1.29 to 6.93; \( p = 0.011 \); HR for non-disabling stroke 6.34, 95% CI 1.45 to 27.71; \( p = 0.014 \)), but there was no risk difference in patients with an ARWMC score of < 7. In a separate analysis restricted to ICSS patients who were randomised to and completed stenting treatment, age was an independent predictor of the risk of stroke, MI or death within 30 days of CAS (relative risk increase 1.17% per 5 years of age, 95% CI 1.01% to 1.37%), as were a right-sided procedure (RR 0.54, 95% CI 0.32 to 0.91), aspirin and clopidogrel in combination prior to CAS (RR 0.59, 95% CI 0.36 to 0.98), smoking status and the severity of index event. The use of an open-cell stent conferred higher risk than use of a closed-cell stent (RR 1.92, 95% CI 1.11 to 3.33), but the use of a cerebral protection device did not modify the risk. In a separate multivariable analysis restricted to ICSS patients who were randomised to and completed endarterectomy, only diastolic blood pressure at baseline was a significant predictor of the risk of stroke, MI or death within 30 days of CEA. Independent risk factors modifying the risk of cranial nerve palsy after CEA in a multivariate analysis were cardiac failure (RR 2.66, 95% CI 1.11 to 6.40), female sex (RR 1.80, 95% CI 1.02 to 3.20), and the degree of contralateral carotid stenosis and time from randomisation to treatment > 14 days (RR 3.33, 95% CI 1.05 to 10.57). The risk of haematoma after CEA was increased in women, by the prescription of anticoagulant drugs pre procedure and in patients with atrial fibrillation.

**Magnetic resonance imaging substudy findings**
A total of 231 patients had MRI before and after treatment. Sixty-two (50%) of 124 patients in the stenting group and 18 (17%) of 107 patients in the endarterectomy group had at least one new ischaemic lesion detected on post-treatment MRI performed a median of 1 day after treatment (adjusted odds ratio 5.21, 95% CI 2.78 to 9.79; \( p < 0.0001 \)).
Primary outcome

In the ITT analysis, the primary outcome event, fatal or disabling stroke between randomisation and end of follow-up, occurred in 52 patients in the stenting group, corresponding to a cumulative 5-year risk of 6.4%, and in 49 patients in the endarterectomy group (5-year risk of 6.5%), without any evidence for a difference in time to first occurrence of an event (HR 1.06, 95% CI 0.72 to 1.57; \( p = 0.76 \)).

Other long-term outcomes

In the ITT analysis, any stroke (5-year risks of 15.2% vs. 9.4%) (HR 1.71, 95% CI 1.28 to 2.30; \( p = 0.0003 \)), as well as the combination of any procedural stroke, procedural death or ipsilateral stroke during follow-up (11.8% vs. 7.2%) (HR 1.72, 95% CI 1.24 to 2.39; \( p = 0.001 \)), occurred significantly more often in the stenting group. However, there was no difference in functional outcome between the groups as assessed by the distribution of mRS scores at 1-year follow-up, 5-year follow-up or at the end of follow-up.

A total of 737 (98.0%) patients in the stenting group and 793 (97.8%) in the endarterectomy group were followed up with carotid ultrasound for a median of 4.0 years after treatment. There was no significant difference in long-term rates of severe carotid restenosis (\( \geq 70\% \)) or occlusion, which occurred in 72 patients in the stenting group (5-year risk of 10.8%) and in 62 patients in the endarterectomy group (5-year risk 8.6% (HR 1.25, 95% CI 0.89 to 1.75; \( p = 0.20 \)).

In the per-protocol analysis of events occurring more than 30 days after completed treatment up to the end of follow-up, there was no significant difference in the rates of ipsilateral stroke in the territory of the treated artery (4.7% vs. 3.4%) (HR 1.29, 95% CI 0.74 to 2.24; \( p = 0.36 \)). However, stroke of any severity occurred more often after stenting (8.9% vs. 5.8%) (HR 1.53, 95% CI 1.02 to 2.31; \( p = 0.039 \)). This difference was largely attributable to stroke occurring in the territory of the contralateral carotid artery or the vertebrobasilar circulation among patients treated with stents, and the majority of these strokes were non-disabling.

Cost–utility analysis

There were no differences in costs or QALYs between the treatments. Mean costs per patient were £7351 (95% CI £6786 to £7915) in the stenting group (\( n = 853 \)) and £6762 (95% CI £6154 to £7369) in the endarterectomy group (\( n = 857 \)). Mean QALYs per patient were 3.247 in the stenting group (95% CI 3.160 to 3.33) and 3.228 in the endarterectomy group (95% CI 3.150 to 3.306). There were no differences in adjusted costs between groups (mean incremental costs for stenting vs. endarterectomy £537, 95% CI –£238 to £1312) or adjusted outcomes (mean QALYs gained –0.010, 95% CI –0.117 to 0.097). The incremental net monetary benefit for stenting compared with endarterectomy was not significantly different from zero at a maximum willingness to pay for a QALY of £20,000 (mean –£723, 95% CI –£3134 to £1670). Sensitivity analyses showed little uncertainty in these findings.

Conclusions

The functional outcome of patients with symptomatic carotid stenosis treated by stenting is similar to endarterectomy. CAS has a higher short-term (periprocedural) risk than CEA in terms of stroke but a lower rate of severe haematoma and it avoids injury to cranial nerves during endarterectomy. The additional short-term risk associated with CAS is largely attributable to non-disabling strokes. More extensive white-matter changes on baseline brain imaging and older age of the patient increase the procedural risks of stenting. The primary analysis of the trial showed that stenting is equivalent to endarterectomy in preventing fatal or disabling stroke up to 10 years after treatment. Severe restenosis or occlusion of the treated carotid artery was rare, with no difference between treatment groups. Stenting also appeared to be as effective as endarterectomy in preventing ipsilateral stroke occurring during follow-up after the
30-day procedural period. Stenting and endarterectomy had similar costs (index procedure costs, follow-up costs and total costs) and outcomes (utility values, QALYs). This was despite the finding in the trial of higher rates of non-disabling strokes in the stenting group. Comprehensive sensitivity analyses showed little uncertainty in this finding. Non-significant differences in utility values and QALYs mirror differences in mRS scores and all-cause mortality found in the trial.

Implications for health care

The data from ICSS show that stenting is a reasonable alternative to endarterectomy, especially if there are features suggesting that the risk of procedural stroke with stenting is likely to be similar or lower than that of endarterectomy (e.g. younger age or less than average severity of white-matter disease). Such patients should be offered stenting after informed consent giving full consideration of the overall periprocedural risks in the relevant groups. In addition to taking into account clinical and imaging features, treatment decisions should take into account patient preferences with reference to the differing nature of the risks with the two procedures. The findings of ICSS mean that there is no reason to prefer either stenting or endarterectomy on economic grounds; other factors should be taken into account when deciding which option to use to treat patients with symptomatic carotid stenosis.

Implications for research

Given the effect of stenting on silent infarction noted in ICSS–MRI substudy, measurement of cognitive function might be an important part of any future study of stenting and/or CEA. Another important area for future studies is identifying the clinical characteristics of patients that determine how likely they are to benefit from revascularisation in the context of optimised medical therapy.

 Trial registration

Current Controlled Trials ISRCTN25337470.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research. Further funding was provided by the Medical Research Council, Stroke Association, Sanofi-Synthélabo and European Union.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme or, originally commissioned by the Medical Research Council (MRC) and now managed by the Efficacy and Mechanism Evaluation programme which is funded by the MRC and NIHR, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

This issue of Health Technology Assessment contains a project originally commissioned by the MRC but managed by the Efficacy and Mechanism Evaluation Programme. The EME programme was created as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is funded by the MRC and NIHR, with contributions from the CSO in Scotland and NISCHR in Wales and the HSC R&D, Public Health Agency in Northern Ireland. It is managed by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) based at the University of Southampton.

The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from the material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC NETSCC, the HTA programme the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme the EME programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Featherstone et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk